search
Back to results

The Effect of Plasma-air-filtration on the Incidence of Surgical Site Infections in Orthopaedic Surgery (EPOS)

Primary Purpose

Orthopaedic Surgery (30 Minutes or Longer)

Status
Completed
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Novaerus NV800 on
Novaerus NV800 off
Novaerus NV800 on or off
Sponsored by
Karolinska Institutet
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Orthopaedic Surgery (30 Minutes or Longer)

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All patients that undergo a 30 minute or longer orthopaedic surgery

Exclusion Criteria:

  • The following surgeries will be excluded: already infected surgical site, defined as: ICD-codes indicating infection, Open fractures, Traumatic wounds, Vacuum assisted wound therapy
  • Patients that have had antibiotics prescribed 2 weeks or less prior to surgery
  • Patients that have actively marked their hospital charts with an added privacy notice

Sites / Locations

  • Danderyds Sjukhus AB

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Exposed patients: Plasma-filter on

Unexposed patients: Plasma-filter off

Mixed patients: Plasma-filter on or off

Arm Description

Those operated with Novaerus NV800 on for at least 2 Days prior to index surgery. This Group will also in the analysis be sub-grouped according to measurements prior to study start into: regular operating theater ultra-Clean operating theaters

Those with Novaerus NV800 off for at least 2 Days prior to index surgery

Those receiving multiple surgeries in different theaters with Novaerus NV800 on or off status will belong to a mixed Group.

Outcomes

Primary Outcome Measures

Number of patients with surgical site infection after orthopaedic surgery, defined as any of the following: using antibiotics targeting Staphylococcus aureus, having ICD-codes or surgery codes indicating postoperative infection.
All definitions are merged into one binary outcome measure as "any(No. > 0)"

Secondary Outcome Measures

Patients using any antibiotics after surgery
This is identified either via hospital information system or from the national drug registry. Usage is defined as withdrawal or prescription of a drug with ATC code within the J01 group.
Number of days with antibiotics
This is identified either via hospital information system or from the national drug registry. Usage is defined as withdrawal or prescription of a drug with ATC code within the J01 group. Number of days is deduced from the prescribed dosage or if not present the average daily dosage for that particular drug is used.
Patients using any antibiotics after surgery
This is identified either via hospital information system or from the national drug registry. Usage is defined as withdrawal or prescription of a drug with ATC code within the J01 group.
Number of days with antibiotics
This is identified either via hospital information system or from the national drug registry. Usage is defined as withdrawal or prescription of a drug with ATC code within the J01 group. Number of days is deduced from the prescribed dosage or if not present the average daily dosage for that particular drug is used.
Death
Any cause of death

Full Information

First Posted
February 9, 2016
Last Updated
June 23, 2022
Sponsor
Karolinska Institutet
Collaborators
The Swedish Research Council
search

1. Study Identification

Unique Protocol Identification Number
NCT02695368
Brief Title
The Effect of Plasma-air-filtration on the Incidence of Surgical Site Infections in Orthopaedic Surgery
Acronym
EPOS
Official Title
The Effect of Air-filtration Through a Plasma Chamber on the Incidence of Surgical Site Infections in Orthopaedic Surgery: a Double-blind, Randomized, Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Completed
Study Start Date
April 10, 2017 (Actual)
Primary Completion Date
December 31, 2021 (Actual)
Study Completion Date
December 31, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Karolinska Institutet
Collaborators
The Swedish Research Council

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study is a multicenter, double-blind, randomized, controlled trial conducted at six major university and teaching hospitals with a catchment population of approximately 2 million. In the current study it has been hypothesized that a non-invasive air cleaner utilizing a plasma chamber can significantly reduce the incidence of surgical site infections (SSIs).
Detailed Description
Despite operating in clean theaters, surface sterilization, and antibiotics, surgical site infections (SSI) after orthopaedic surgery have an estimated incidence of 1-4%. This feared complication is associated with long-term antibiotics, repeated surgeries, prolonged hospital stays, economic burden and a poorer end result for individual patients. It is therefore of great importance to prevent SSI.While skin bacteria and contaminated surfaces have generally been claimed to be the main cause of infections, there are estimates that approximately 20% of hospital-acquired infections are air-transmitted, making this an interesting intervention target. Novaerus is an air-cleaner that sterilizes the air particles through a plasma chamber. Air in the operating theatre is pumped through the chamber (80-380 m3/Hr) and by using a small current it transforms the gas in the vicinity of the electrode into plasmaand eradicates any bacteria that pass through.The small size of the machine allows it to fit into any operating theater without interfering with existing equipment. This technology can reduce the number of colony forming units (CFU) when in hospital settings. In non-randomized settings it has been correlated to reduced respiratory infections, reduced personnel sick-leave, and absence of severe infectious outbreaks. Its effect has not been validated in randomized controlled trials. Both local and national registry data will be used according to availability.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Orthopaedic Surgery (30 Minutes or Longer)

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
45000 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Exposed patients: Plasma-filter on
Arm Type
Experimental
Arm Description
Those operated with Novaerus NV800 on for at least 2 Days prior to index surgery. This Group will also in the analysis be sub-grouped according to measurements prior to study start into: regular operating theater ultra-Clean operating theaters
Arm Title
Unexposed patients: Plasma-filter off
Arm Type
Experimental
Arm Description
Those with Novaerus NV800 off for at least 2 Days prior to index surgery
Arm Title
Mixed patients: Plasma-filter on or off
Arm Type
Experimental
Arm Description
Those receiving multiple surgeries in different theaters with Novaerus NV800 on or off status will belong to a mixed Group.
Intervention Type
Device
Intervention Name(s)
Novaerus NV800 on
Intervention Description
The air-cleaner sterilizes the air particles through a plasma chamber. Air in the operating theatre is pumped through the chamber (80 - 380 m3/Hr) and by using a small current it transforms the gas in the vicinity of the electrode into plasma and eradicates any bacteria that pass through. The air-cleaner has to have been turned on for at least 2 days prior to the surgical intervention.
Intervention Type
Device
Intervention Name(s)
Novaerus NV800 off
Intervention Description
The machine decribed above is running but the plasma filter chamber isn't active, i.e. the placebo group.
Intervention Type
Device
Intervention Name(s)
Novaerus NV800 on or off
Intervention Description
Patients with multiple surgeries that have been operated during both periods when the apparatus has been on and off will belong to this mixed group.
Primary Outcome Measure Information:
Title
Number of patients with surgical site infection after orthopaedic surgery, defined as any of the following: using antibiotics targeting Staphylococcus aureus, having ICD-codes or surgery codes indicating postoperative infection.
Description
All definitions are merged into one binary outcome measure as "any(No. > 0)"
Time Frame
Within 12 weeks after surgery
Secondary Outcome Measure Information:
Title
Patients using any antibiotics after surgery
Description
This is identified either via hospital information system or from the national drug registry. Usage is defined as withdrawal or prescription of a drug with ATC code within the J01 group.
Time Frame
Two treatment days or more during the first 30 postoperative days
Title
Number of days with antibiotics
Description
This is identified either via hospital information system or from the national drug registry. Usage is defined as withdrawal or prescription of a drug with ATC code within the J01 group. Number of days is deduced from the prescribed dosage or if not present the average daily dosage for that particular drug is used.
Time Frame
During the first 30 postoperative days
Title
Patients using any antibiotics after surgery
Description
This is identified either via hospital information system or from the national drug registry. Usage is defined as withdrawal or prescription of a drug with ATC code within the J01 group.
Time Frame
Two treatment days or more during the first 90 postoperative days
Title
Number of days with antibiotics
Description
This is identified either via hospital information system or from the national drug registry. Usage is defined as withdrawal or prescription of a drug with ATC code within the J01 group. Number of days is deduced from the prescribed dosage or if not present the average daily dosage for that particular drug is used.
Time Frame
Two treatment days or more during the first 90 postoperative days
Title
Death
Description
Any cause of death
Time Frame
during the first 2 postoperative years

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients that undergo a 30 minute or longer orthopaedic surgery Exclusion Criteria: The following surgeries will be excluded: already infected surgical site, defined as: ICD-codes indicating infection, Open fractures, Traumatic wounds, Vacuum assisted wound therapy Patients that have had antibiotics prescribed 2 weeks or less prior to surgery Patients that have actively marked their hospital charts with an added privacy notice
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Max Gordon, M.D, PhD
Organizational Affiliation
Danderyd Hospital, Stockholm, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
Danderyds Sjukhus AB
City
Stockholm
ZIP/Postal Code
182 88
Country
Sweden

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35115346
Citation
Persson A, Atroshi I, Tyszkiewicz T, Hailer N, Lazarinis S, Eisler T, Brismar H, Mukka S, Kernell PJ, Mohaddes M, Skoldenberg O, Gordon M. EPOS trial: the effect of air filtration through a plasma chamber on the incidence of surgical site infection in orthopaedic surgery: a study protocol of a randomised, double-blind, placebo-controlled trial. BMJ Open. 2022 Feb 3;12(2):e047500. doi: 10.1136/bmjopen-2020-047500.
Results Reference
derived

Learn more about this trial

The Effect of Plasma-air-filtration on the Incidence of Surgical Site Infections in Orthopaedic Surgery

We'll reach out to this number within 24 hrs